Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1211289.RACBZ9V6AGOOM0Aa6K2PSwxcBTyYwJ8Cfwk5hYTWPUNh8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1211289.RACBZ9V6AGOOM0Aa6K2PSwxcBTyYwJ8Cfwk5hYTWPUNh8130_assertion type Assertion NP1211289.RACBZ9V6AGOOM0Aa6K2PSwxcBTyYwJ8Cfwk5hYTWPUNh8130_head.
- NP1211289.RACBZ9V6AGOOM0Aa6K2PSwxcBTyYwJ8Cfwk5hYTWPUNh8130_assertion description "[Enrolled patients with advanced (stage IIIB/IV) KRAS wild type (WT) lung adenocarcinoma refractory to one or two courses of prior chemotherapy were treated with erlotinib at 150mg/day.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1211289.RACBZ9V6AGOOM0Aa6K2PSwxcBTyYwJ8Cfwk5hYTWPUNh8130_provenance.
- NP1211289.RACBZ9V6AGOOM0Aa6K2PSwxcBTyYwJ8Cfwk5hYTWPUNh8130_assertion evidence source_evidence_literature NP1211289.RACBZ9V6AGOOM0Aa6K2PSwxcBTyYwJ8Cfwk5hYTWPUNh8130_provenance.
- NP1211289.RACBZ9V6AGOOM0Aa6K2PSwxcBTyYwJ8Cfwk5hYTWPUNh8130_assertion SIO_000772 25129367 NP1211289.RACBZ9V6AGOOM0Aa6K2PSwxcBTyYwJ8Cfwk5hYTWPUNh8130_provenance.
- NP1211289.RACBZ9V6AGOOM0Aa6K2PSwxcBTyYwJ8Cfwk5hYTWPUNh8130_assertion wasDerivedFrom befree-2016 NP1211289.RACBZ9V6AGOOM0Aa6K2PSwxcBTyYwJ8Cfwk5hYTWPUNh8130_provenance.
- NP1211289.RACBZ9V6AGOOM0Aa6K2PSwxcBTyYwJ8Cfwk5hYTWPUNh8130_assertion wasGeneratedBy ECO_0000203 NP1211289.RACBZ9V6AGOOM0Aa6K2PSwxcBTyYwJ8Cfwk5hYTWPUNh8130_provenance.